Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21011264 | 0.95 | MEN1 (0.42) | CYP3A4POLBDDB1CRBNCYP17A1 | |
| SCHEMBL18256732 | 0.94 | NAAA (0.41) | POLBALDH1A1MEN1KMT2ANAAA | |
| SCHEMBL15198823 | 0.94 | NAAA (0.41) | CYP3A4POLBDDB1CRBNCYP17A1 | |
| SCHEMBL847109 | 0.94 | POLB (0.35) | CYP3A4POLBDDB1CRBNCYP17A1 | |
| SCHEMBL12938576 | 0.93 | POLB (0.38) | CYP3A4POLBDDB1CRBNCYP17A1 | |
| SCHEMBL846827 | 0.92 | ALDH1A1 (0.47) | DDB1CRBNALDH1A1KMT2A | |
| SCHEMBL24885613 | 0.90 | NAAA (0.44) | POLBALDH1A1MEN1KMT2ANAAA | |
| SCHEMBL663919 | 0.80 | ATM (0.50) | CYP3A4POLBALDH1A1MEN1KMT2A | |
| SCHEMBL18257753 | 0.79 | CHRM5 (0.34) | — | |
| SCHEMBL12938624 | 0.79 | NAAA (0.45) | CYP3A4ALDH1A1MEN1KMT2ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190091338-A1 | MIKTO-ARM STAR POLYMERS FOR DELIVERY OF THERAPEUTIC AGENTS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190091338-A1 | MIKTO-ARM STAR POLYMERS FOR DELIVERY OF THERAPEUTIC AGENTS | COQ8A, COQ8B, STARD7 | CYP3A4 1255/4885POLB 485/4885DDB1 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.